Pular para o conteúdo principal
Ranking Invest

NTLA - Intellia Therapeutics, Inc.

Segmento: HealthcareIntellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Análise Ranking Invest

Valuation estimado
-$ 937.10 Mi
Valor de Mercado
$ 1.65 Bi
Desconto (AV)-275.6%
IVR
-0.57A companhia vale -0,57 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-1.02O valuation alternativo equivale a -102% do valor de mercado da companhia.
MLL
-1.02O lucro líquido dos controladores em 16 trimestres equivale a -102% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 727.71 Mi

Dívida Líquida

-$ 106.13 Mi

L4T

-$ 399.98 Mi

MM4T

-795.78%

Indicadores Básicos

ROE

-54.96%

Índices de Previsibilidade

Receita Líquida

F0.31

Lucro

A0.10

Margem

C0.34

Índices de Tendência

Receita Líquida

D1.43

Lucro

C3.76

Margem

D0.57

Índices de Endividamento

DIV/PAT

-0.15

DIV/L4T

0.27

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.